Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
Help & Tutorial 
Cancel anytime
- Chart
- Upturn Summary
- Highlights
- Revenue
- Valuation
- Analyst Ratings
Upturn AI SWOT - About
Nuvation Bio Inc (NUVB)
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)
Stock price based on last close (see disclosures)
- ALL
- YEAR
- MONTH
- WEEK
Upturn Advisory Summary
03/13/2025: NUVB (2-star) is currently NOT-A-BUY. Pass it for now.
Upturn Star Rating
Below Average Performance
These Stocks/ETFs, based on Upturn Advisory, often underperform the market, warranting careful consideration before investing.
AI Based Fundamental Rating
Not Recommended Performance
These Stocks/ETFs, based on Upturn Advisory, consistently fall short of market performance, signaling caution before investing.
Analysis of Past Performance
Type Stock | Historic Profit -3.19% | Avg. Invested days 35 | Today’s Advisory PASS |
Upturn Star Rating | Upturn Advisory Performance  1.0 | Stock Returns Performance  1.0 |
| Profits based on simulation | Last Close 03/13/2025 |
Key Highlights
Company Size Small-Cap Stock | Market Capitalization 616.40M USD | Price to earnings Ratio - | 1Y Target Price 8.2 |
Price to earnings Ratio - | 1Y Target Price 8.2 | ||
Volume (30-day avg) 2466218 | Beta 1.47 | 52 Weeks Range 1.66 - 3.97 | Updated Date 04/1/2025 |
52 Weeks Range 1.66 - 3.97 | Updated Date 04/1/2025 | ||
Dividends yield (FY) - | Basic EPS (TTM) -2.04 |
Analyzing Revenue: Products, Geography and Growth
Revenue by Products
Revenue by Geography
Earnings Date
Report Date - | When - | Estimate - | Actual - |
Profitability
Profit Margin - | Operating Margin (TTM) -944.53% |
Management Effectiveness
Return on Assets (TTM) -18.02% | Return on Equity (TTM) -106.27% |
Valuation
Trailing PE - | Forward PE - | Enterprise Value 102297784 | Price to Sales(TTM) 78.29 |
Enterprise Value 102297784 | Price to Sales(TTM) 78.29 | ||
Enterprise Value to Revenue 12.99 | Enterprise Value to EBITDA 2.23 | Shares Outstanding 337679008 | Shares Floating 228679350 |
Shares Outstanding 337679008 | Shares Floating 228679350 | ||
Percent Insiders 26.68 | Percent Institutions 58.96 |
Analyst Ratings
Rating 4.75 | Target Price 7.5 | Buy 1 | Strong Buy 3 |
Buy 1 | Strong Buy 3 | ||
Hold - | Sell - | Strong Sell - | |
Strong Sell - |
Upturn AI SWOT
Nuvation Bio Inc
Company Overview
History and Background
Nuvation Bio Inc. was founded in 2018 by Dr. David Hung. The company focuses on developing therapies for unmet medical needs in oncology. It went public via a SPAC merger in February 2021.
Core Business Areas
- Oncology Drug Development: Focuses on discovering and developing targeted oncology therapies.
Leadership and Structure
Dr. David Hung serves as the Founder, President, and CEO. The company has a typical structure with research, development, and administrative departments.
Top Products and Market Share
Key Offerings
- NUV-868: A BDNF-TRKB-RAS inhibitor. Currently in Phase 1 clinical trials. Competitors include companies developing similar RAS inhibitors like Amgen (AMGN) and Mirati Therapeutics (MRTX). Market share data not available at this stage of development.
Market Dynamics
Industry Overview
The oncology drug development industry is highly competitive and constantly evolving with significant unmet needs remaining. Precision medicine and targeted therapies are increasingly important.
Positioning
Nuvation Bio Inc. is a clinical-stage biopharmaceutical company focused on developing innovative therapies targeting significant unmet needs in oncology. They aim to develop differentiated therapies that address the underlying drivers of cancer.
Total Addressable Market (TAM)
The global oncology market is estimated to be worth hundreds of billions of dollars. Nuvation Bio Inc. is targeting specific cancer types and pathways within this larger market. TAM for their initial targets may be around $5-10 Billion.
Upturn SWOT Analysis
Strengths
- Experienced leadership team
- Promising pipeline of oncology drugs
- Strong focus on innovative therapies
- RAS Inhibitor
- BDNF-TRKB-RAS inhibitors
Weaknesses
- Clinical-stage company with no approved products
- High R&D expenses
- Dependence on clinical trial outcomes
- Limited cash runway until next funding source
- Reliance on a small product pipeline
Opportunities
- Successful clinical trial results
- Partnerships with larger pharmaceutical companies
- Expansion of the pipeline
- Potential for breakthrough therapies
- Address unmet medical needs in oncology
Threats
- Clinical trial failures
- Competition from established pharmaceutical companies
- Regulatory hurdles
- Patent challenges
- Changes in the market for oncology drugs
Competitors and Market Share
Key Competitors
- AMGN
- MRTX
- LLY
Competitive Landscape
Nuvation Bio Inc. faces competition from established pharmaceutical companies and other biotechnology companies developing oncology therapies. Nuvation Bio's advantage lies in its innovative approach and focus on difficult-to-treat cancers. Disadvantages include the company's early stage and lack of commercialized products.
Major Acquisitions
Growth Trajectory and Initiatives
Historical Growth: Historical growth is limited due to its early stage. Growth is primarily reflected in pipeline advancement.
Future Projections: Future growth is tied to successful clinical trials, potential regulatory approvals, and commercialization of products. Analyst estimates vary widely.
Recent Initiatives: Focus on advancing the NUV-868 clinical program and expanding its pipeline.
Summary
Nuvation Bio is a clinical-stage biopharmaceutical company with a promising but risky pipeline. Its focus on innovative oncology therapies targeting unmet needs positions it for potential future growth if clinical trials are successful. However, it faces substantial competition and financial risks inherent in drug development. The company's success hinges on the advancement of its key programs.
Similar Companies
AMGN
Amgen Inc
AMGN
Amgen Inc
ARRY
Array Technologies Inc
ARRY
Array Technologies Inc
Sources and Disclaimers
Data Sources:
- Company Website
- SEC Filings (e.g., 10-K, 10-Q)
- ClinicalTrials.gov
- Analyst Reports
- Yahoo Finance
- Google Finance
Disclaimers:
The information provided is for informational purposes only and should not be considered as financial advice. Investment decisions should be based on individual research and consultation with a qualified financial advisor. Market share data is approximate and based on available information.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About Nuvation Bio Inc
Exchange NYSE | Headquaters New York, NY, United States | ||
IPO Launch date 2020-08-24 | Founder, President, CEO & Chairman Dr. David T. Hung M.D. | ||
Sector Healthcare | Industry Biotechnology | Full time employees 220 | Website https://www.nuvationbio.com |
Full time employees 220 | Website https://www.nuvationbio.com | ||
Nuvation Bio Inc., a clinical-stage biopharmaceutical company, focuses on unmet needs in oncology by developing differentiated and novel therapeutic candidates. Its lead product candidate is taletrectinib, an ROS1 inhibitor specifically designed for the treatment of patients with ROS1+ non-small cell lung cancer; Safusidenib, a novel, oral, potent, brain penetrant, targeted inhibitor of mutant isocitrate dehydrogenase 1 in phase 2 clinical trials; NUV-1511, a drug-drug conjugate for use in chemotherapy agent that suppresses the growth of various advanced solid tumors; NUV-868, a binding domain 2 selective, oral, small molecule bromodomain and extra-terminal inhibitor that inhibits bromodomain-containing protein 4. The company was founded in 2018 and is headquartered in New York, New York.
Upturn is now on iOS and Android!
Experience Upturn on your mobile. Install it now!
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.